Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, safety, and tolerability of gemcitabine and cisplatin in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma.

Trial Profile

Efficacy, safety, and tolerability of gemcitabine and cisplatin in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veliparib (Primary) ; Cisplatin; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Jan 2018 Results published in the Cancer
    • 16 Jun 2014 New trial record
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top